These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15612375)

  • 1. Clinical management of osteogenesis imperfecta.
    Sillence DO; Morley K; Ault JE
    Connect Tissue Res; 1995; 31(4):S15-21. PubMed ID: 15612375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rehabilitation of infants with osteogenesis imperfecta.
    Binder H
    Connect Tissue Res; 1995; 31(4):S37-9. PubMed ID: 15612379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.
    Jacobsen CM; Schwartz MA; Roberts HJ; Lim KE; Spevak L; Boskey AL; Zurakowski D; Robling AG; Warman ML
    Bone; 2016 Sep; 90():127-32. PubMed ID: 27297606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OIM and related animal models of osteogenesis imperfecta.
    Shapiro JR; Mcbride DJ; Fedarko NS
    Connect Tissue Res; 1995; 31(4):265-8. PubMed ID: 15612365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontiers in rehabilitation medicine: osteogenesis imperfecta, overview of a conference.
    Byers PH; Marini JC; Gerber L
    Connect Tissue Res; 1995; 31(4):253-5. PubMed ID: 15612362
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe osteogenesis imperfecta Type-III and its challenging treatment in newborn and preschool children. A systematic review.
    Sinikumpu JJ; Ojaniemi M; Lehenkari P; Serlo W
    Injury; 2015 Aug; 46(8):1440-6. PubMed ID: 25943292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteogenesis imperfecta.
    Marini JC; Forlino A; Bächinger HP; Bishop NJ; Byers PH; Paepe A; Fassier F; Fratzl-Zelman N; Kozloff KM; Krakow D; Montpetit K; Semler O
    Nat Rev Dis Primers; 2017 Aug; 3():17052. PubMed ID: 28820180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New trends in the treatment of osteogenesis imperfecta type III - own experience.
    Jakubowska-Pietkiewicz E; Chlebna-Sokół D
    Ortop Traumatol Rehabil; 2008; 10(6):593-601. PubMed ID: 19153548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased intra-cortical porosity reduces bone stiffness and strength in pediatric patients with osteogenesis imperfecta.
    Vardakastani V; Saletti D; Skalli W; Marry P; Allain JM; Adam C
    Bone; 2014 Dec; 69():61-7. PubMed ID: 25238898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta.
    Rauch F; Lalic L; Roughley P; Glorieux FH
    J Bone Miner Res; 2010 Jun; 25(6):1367-74. PubMed ID: 19929435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteogenesis imperfecta: diagnosis and treatment.
    Biggin A; Munns CF
    Curr Osteoporos Rep; 2014 Sep; 12(3):279-88. PubMed ID: 24964776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrastructural and histological findings on examination of skin in osteogenesis imperfecta: a novel study.
    Balasubramanian M; Wagner BE; Peres LC; Sobey GJ; Parker MJ; Dalton A; Arundel P; Bishop NJ
    Clin Dysmorphol; 2015 Apr; 24(2):45-54. PubMed ID: 25436829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel transgenic murine model with persistently brittle bones simulating osteogenesis imperfecta type I.
    Liu Y; Wang J; Liu S; Kuang M; Jing Y; Zhao Y; Wang Z; Li G
    Bone; 2019 Oct; 127():646-655. PubMed ID: 31369917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-phenotype relationship in a large cohort of osteogenesis imperfecta patients with COL1A1 mutations revealed by a new scoring system.
    Li LJ; Lyu F; Song YW; Wang O; Jiang Y; Xia WB; Xing XP; Li M
    Chin Med J (Engl); 2019 Jan; 132(2):145-153. PubMed ID: 30614853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteogenesis imperfecta: practical treatment guidelines.
    Antoniazzi F; Mottes M; Fraschini P; Brunelli PC; Tatò L
    Paediatr Drugs; 2000; 2(6):465-88. PubMed ID: 11127846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type V osteogenesis imperfecta: a new form of brittle bone disease.
    Glorieux FH; Rauch F; Plotkin H; Ward L; Travers R; Roughley P; Lalic L; Glorieux DF; Fassier F; Bishop NJ
    J Bone Miner Res; 2000 Sep; 15(9):1650-8. PubMed ID: 10976985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
    Zacharin M; Bateman J
    J Pediatr Endocrinol Metab; 2002 Feb; 15(2):163-74. PubMed ID: 11874181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique micro- and nano-scale mineralization pattern of human osteogenesis imperfecta type VI bone.
    Fratzl-Zelman N; Schmidt I; Roschger P; Roschger A; Glorieux FH; Klaushofer K; Wagermaier W; Rauch F; Fratzl P
    Bone; 2015 Apr; 73():233-41. PubMed ID: 25554599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.